Compass Therapeutics Drops Sharply As Trial Crossover Complicates Survival Data In Bile Duct Cancer Patients

All NewsApril 27, 2026

Compass Therapeutics says tovecimig misses overall survival endpoint in biliary tract cancer study, but data shows progression-free survival and response rates.

Latest Ratings for CMPX

DateFirmActionFromTo Jan 2022B. Riley SecuritiesInitiates Coverage OnBuy Dec 2021Raymond JamesInitiates Coverage OnOutperform Dec 2021SVB LeerinkInitiates Coverage OnOutperform

View More Analyst Ratings for CMPX

View the Latest Analyst Ratings

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent